menu
    • menu
    [{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Nevakar","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Nevakar \/ Par Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Par Pharmaceutical"},{"orgOrder":0,"company":"Nevakar","sponsor":"Endo International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nevakar \/ Endo International","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Endo International"}]

    Find Clinical Drug Pipeline Developments & Deals for Ephedrine Sulfate

    Menu

    Ephedrine Sulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            MAGHREB PHARMA
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market

                            Details : Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial used to treat the symptoms of various bacterial infections in the skin, lungs, stomach, pelvis, and urinary tract.

                            Product Name : Ephedrine Sulfate-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 05, 2021

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            MAGHREB PHARMA
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial i...

                            Details : The launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz® (ephedrine sulfate injection) Injection, 50 mg/mL is approved by the U.S. Food and Drug Administration (USFDA).

                            Product Name : Ephedrine Sulfate-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 29, 2021

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nexus Pharmaceuticals

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Nexus Pharmaceuticals

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nexus Pharmaceuticals, Inc. Receives FDA Approval for EMERPHED® (ephedrine sulfate injection) Pre-Filled Syri...

                            Details : Emerphed (ephedrine sulfate) is a sympathomimetic amine, an agonist at alpha- and beta-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons.

                            Product Name : Emerphed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 03, 2023

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nevakar

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Nevakar

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Par Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nevakar Injectables Receives U.S. FDA Approval of Ready-to-Use Ephedrine Injection in a Prefilled Syringe

                            Details : Ephedrine Sulfate Injection (“Ephedrine”) in a prefilled syringe is a widely used injectable vasopressor agent indicated for the treatment of clinically important hypotension occurring during surgery.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 28, 2022

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Par Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nevakar

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Nevakar

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Endo International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials

                            Details : Ephedrine is a widely used injectable vasopressor agent indicated for the treatment of clinically important hypotension occurring during surgery, Ephedrine sulfate injection, a formulation pre-diluted to a 5mg/mL concentration and supplied in a 10mL vial...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2022

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Endo International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nexus Pharmaceuticals

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Nexus Pharmaceuticals

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nexus Pharmaceuticals Receives Patent for EMERPHED® Ready-To-Use Ephedrine Sulfate Injection

                            Details : Ephedrine Sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

                            Product Name : Emerphed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 17, 2021

                            Lead Product(s) : Ephedrine Sulfate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth